Key Highlights
- Loss per share was USD 11.02 against an estimate of a USD 1.10 loss.
- Research and development expenses increased 39% to USD 10.84 million.
- Loss on change in Fair Value of Tranche Liability increased by USD 33.1 million.
- Cash and cash equivalents were USD 100.4 million at September 30.
Surrozen (NASDAQ:SRZN) reported a third quarter 2026 loss per share of USD 11.02, against an estimate of a USD 1.10 loss and a USD 8.36 loss in the third quarter of 2025. The company reported no Revenue in the quarter, against an estimate of USD 475 thousand.
The loss from operations was USD 17.64 million, compared with USD 10.89 million a year earlier. Total operating expenses were USD 17.64 million, against USD 11.87 million.
Operating Expenses and Tranche Liability
Research and development expenses were USD 10.84 million, compared with USD 7.77 million, an increase of USD 3.1 million, or 39%. The filing attributes this primarily to a USD 2.1 million increase in research and Manufacturing costs for SZN-8141 and a USD 0.9 million increase in employee-related costs. General and administrative expenses were USD 6.81 million, compared with USD 4.09 million.
The loss on change in fair value of the tranche liability increased by USD 33.1 million, or 81%, which the filing attributes to a noncash change in fair value related to a private placement. Interest income was USD 912 thousand, against USD 911 thousand.
Nine-Month Results
For the nine months ended September 30, 2026, the loss per share was USD 18.06, compared with USD 8.49. Total operating expenses were USD 48.47 million, against USD 32.40 million, and the loss from operations was USD 38.47 million, against USD 29.45 million.
Revenue for the nine months was USD 10.0 million, compared with USD 2.95 million. Research and Development expenses for the nine months were USD 28.65 million, against USD 20.37 million, and general and administrative expenses were USD 19.82 million, against USD 12.03 million.
Clinical Programs and Liquidity
The company received FDA clearance of its IND application for SZN-8141 in October 2026 and dosed its first patient in a Phase 1b/2a study in patients with diabetic macular edema, called DUET. The filing also states that remigromig, formerly known as MK-3000 and a Fzd4 monotherapy, achieved its primary endpoint in a Phase 2/3 clinical trial in diabetic macular edema.
As of September 30, 2026, the company had cash and cash equivalents of USD 100.4 million and an accumulated Deficit of USD 734.3 million. The filing also describes an April 2024 related party sublease of approximately 6,102 square feet of office and laboratory space to Nura Bio.
The filing reports an accumulated deficit of USD 734.3 million as of September 30, 2026, and states that the company expects operating expenses to continue to be significant in connection with its ongoing preclinical studies. It also describes a sublease of approximately 6,102 square feet of office and laboratory space to Nura Bio, Inc., a related party.
Surrozen Q3 2026 Earnings: Key Takeaways
Surrozen reported a third quarter 2026 loss per share of USD 11.02 and research and development expenses of USD 10.84 million. Cash and cash equivalents were USD 100.4 million, and the company dosed its first patient in the DUET study.
_11_16_2026_19_56_26_124029.jpg)





Please wait processing your request...